Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)

OBJECTIVES: Despite advances in systemic lupus erythematosus (SLE) treatment, many patients suffer from the disease and side effects. Atacicept is a fusion protein that blocks B-lymphocyte stimulator and a proliferation-inducing ligand, which are increased in patients with SLE. METHODS: In this doub...

Descripción completa

Detalles Bibliográficos
Autores principales: Isenberg, David, Gordon, Caroline, Licu, Daiana, Copt, Samuel, Rossi, Claudia Pena, Wofsy, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4680140/
https://www.ncbi.nlm.nih.gov/pubmed/24951103
http://dx.doi.org/10.1136/annrheumdis-2013-205067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4680140/
https://www.ncbi.nlm.nih.gov/pubmed/24951103
http://dx.doi.org/10.1136/annrheumdis-2013-205067

Ejemplares similares